Palvella Files FDA Bid for QTORIN Rapamycin in Rare Disease
WAYNE, PA — Palvella Therapeutics Inc. (Nasdaq: PVLA) has completed its application for U.S. approval of QTORIN 3.9% rapamycin anhydrous gel to treat microcystic lymphatic malformations, moving the Wayne-based biotechnology …
Palvella Files FDA Bid for QTORIN Rapamycin in Rare Disease Read More